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Background: Humans are exposed to tributyltin (TBT), previously used as an antifouling paint in ships, mainly
through fish consumption. As TBT is a known obesogen, we studied the association of placenta TBT and other
organotin compounds (OTCs) with ponderal index (PI) and growth during the first 18 months of life in boys.
Methods: In a prospective Finnish study, 110 placenta samples were collected from mothers of boys born in 1997–1999
with (n = 55) and without (n = 55) cryptorchidism. To account for the original study design, linear regression, weighted for
sampling fractions of boys with (121/55) and without (5677/55) cryptorchidism from the total cohort, was used to study
the association between placenta OTCs and children’s weight, length, growth rates and PI up to 18 months of age.
Results: Placenta TBT concentrations were above the limit of quantification (LOQ) in 99% of the samples. However,
monobutyltin (MBT), dibutyltin (DBT) and triphenyltin (TPhT) concentrations were below LOQ in 90%, 35% and 57% of
samples, respectively. Placenta TBT was positively associated (p = 0.024) with weight gain during the first three months of
life, but no other significant associations were observed for weight or length gain. Also, no significant associations
between placenta OTC concentrations and child length, weight or PI at any time point were found.
Conclusions: We observed a trend towards higher weight gain from birth to 3 months of age with increasing placenta
TBT concentration. These results should be interpreted with caution because obesogenic effects in animal experiments
were seen after in-utero TBT exposures to doses that were orders of magnitude higher. Also the number of study subjects
included in this study was limited.
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The organotin compounds (OTCs) tributyltin (TBT) and
triphenyltin (TPhT) have strong biocidal activity and have
been used e.g. in antifouling paints in boats and ships.
TPhT has also been used as an agricultural pesticide [1].
The detrimental effects following antifouling use of TBT,
and TPhT are of most environmental concern and have
been extensively reviewed by Graceli et al. [2]. In brief,* Correspondence: panu.rantakokko@thl.fi
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article, unless otherwise stated.TBT is considered to be a chronic contaminant and very
low concentrations in water are known have e.g. the fol-
lowing effects: levels > 1 ng/l limit cell division in phyto-
plankton and zooplankton reproduction; levels > 2 ng/l are
responsible for shell calcification anomalies in the oyster
Crassostrea gigas; levels > 20 ng/l impair bivalve mollusc
reproduction by impairing the reproductive function and
can induce imposex, intersex and the formation of ovo-
testis. Additionally, OTs may accumulate in birds and sea
mammals and can limit growth rates and photosynthesis
in algae. Due to the detrimental environmental effects
their use in antifouling [3] and agricultural applications [4]
has been banned in Europe. Also, the scientific panel oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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lished a group Tolerable Daily Intake (TDI) of 250 ng/kg
body weight for the sum of dibutyltin (DBT), TBT, TPhT,
and dioctyltin (DOT) based on the immunotoxicity of
these compounds [5]. For humans, fish is considered to be
the main source of TBT and TPhT exposure [6,7]. How-
ever, PVC plastics, e.g. vinyl blinds, vinyl sidings and wall-
paper, may contain large amounts of OTCs and could be a
significant source of butyltin and octyltin exposure for
children through direct dermal contact and dust ingestion
and inhalation [8,9].
The current epidemic of overweight has sparked the
discussion on the role of environmental contaminants
on this development. The first systematic review on the
possible contribution of low level chemical exposure to the
obesity epidemic was made by Baillie-Hamilton [10] and
the “obesogen” concept was launched in a commentary of
this study [11]. Especially the possibility that prenatal ex-
posure to obesogenic chemicals may permanently program
those exposed to greater propensity to obesity later in life
has gained considerable interest. For humans tobacco
smoke is an established prenatal obesogen [12-14]. Ani-
mal experiments and epidemiological studies have listed
other suspected obesogens such as diethylstilbestrol
(DES), bisphenol A (BPA), phytoestrogens, organochlor-
ine pesticides, polychlorinated biphenyls (PCBs), phtha-
lates and perfluorinated alkyl acids (PFAAs) [15-17].
For example, a number of studies have found an associ-
ation between prenatal organochlorine (OC) compound
exposure and increased BMI in infancy [18], childhood
[19,20] and adulthood [21].
To date, TBT is the best studied environmental obe-
sogen. In vitro, TBT enhances adipogenesis, triglyceride
storage and expression of adipogenic marker genes
[22-24] , causes increases in adipogenic capacity and re-
duction of the osteogenic capacity of adipose-derived stro-
mal stem cells (ADSCs) [25]. Also, in utero exposure to
TBT causes lipid accumulation into various adipose depots
at the expense of bone [26] and similar effects have been
observed even at transgenerational level [27]. Peroxisome
proliferator-activated receptor gamma (PPAR-γ) has a
central role in TBT-induced adipocyte differentiation [24].
Despite good in vitro and in vivo evidence of the obeso-
genic effects of TBT, there are no human epidemiological
studies on the topic. This study aimed at evaluating the
possible impact of prenatal exposure to OTCs (monobu-
tyltin (MBT), dibutyltin (DBT), TBT, TPhT) on the pon-
deral index (PI) and growth during the first 18 months of
life among Finnish boys.Methods
The study was conducted according to the Helsinki II
declaration after informed oral and written consent ofthe parents. The ethical committee of Turku University
Hospital (Finland: 7/1996, 6/2001) approved the study.
Study population and placenta samples
Placenta samples were obtained from a Finnish prospect-
ive, longitudinal cohort study performed in 1997–1999 at
Turku University Hospital, Turku, Finland. The primary
aim of this study was to establish contemporary preva-
lence rates for cryptorchidism and hypospadias, and at
evaluating risk factors by means of a questionnaire and
biological samples (blood, placenta, and breast milk). Re-
cruitment strategy, inclusion criteria and clinical examin-
ation of the children have been described in previous
publications [28-30]. Placenta samples were collected from
mothers of healthy boys (n = 55) and mothers of boys with
cryptorchidism (n = 55) at birth in a nested case–control
design. The matching criteria were: parity, maternal smok-
ing (yes/no), diabetes (yes/no), gestational age (±7 days)
and date of birth (±14 days).
Chemical and anthropometric measurements
The analyses used to estimate exposure were prospectively
planned to include persistent and non-persistent chemicals in
breast milk and placenta (EU grant QLK4-CT-2001-00269),
most of which have been previously reported, including
OTCs from placentas but not from breast milk [29,31-38].
To analyse OTCs from placenta samples, perdeuterated
OTCs used as internal standards were added to 0.25 g of
dried placenta homogenate. Homogenates were digested
with tetramethyl ammonium hydroxide and methanol.
Samples were then buffered to pH4 with sodium acetate-
acetic acid and OTCs were ethylated with sodiumte-
traethylborate. Ethylated OTCs were extracted to hexane
and purified with alumina column. Purified extracts were
concentrated and subjected to gas chromatography/mass
spectrometry (GC/MS) analysis (Agilent 6890 GC/Waters
Autospec Ultima high-resolution MS). Limits of quantifi-
cation (LOQs) were 0.1 ng/g fresh weight (fw) for MBT
and DBT, and 0.02 ng/g fw for TBT and TPhT.
Weight and length was obtained for 110 boys at birth,
for 107 at 3 months and for 91 at 18 months. Ponderal
index (PI) was calculated as kg/m3. Weight and length
gain (kg/week, cm/week) were calculated from birth to
3 months and from 3 to 18 months.
Statistics
Background characteristics of mothers and boys were cal-
culated as previously described [33,34,38] The concentra-
tions of each OTC compound and the sum of OTCs were
grouped into two or three categories, depending on the dis-
tribution of concentrations of each OTC. Concentrations
below the LOQ were treated as one-half of the respective
LOQ in the calculations [24]. Means of weight, length and
PI in each OTC category were also calculated.
Table 1 Population characteristics (N, medians, 2.5th and
97.5th percentiles) for mothers and boys
N 110
Maternal age (years) 28.2 (21.0-40.0)
Maternal pregnancy BMI (kg/m2) 22.8 (17.9-34.7)
Diabetes (yes, No) 9, 100





Gestational age (days) 280 (256, 295)
WGA (%)a −0.90 (−22.5, 22.6)
Prematurity (N)b 4
Weight at birth (kg) 3.59 (2.72, 4.52)
Weight at 3 months (kg) 6.48 (5.27, 7.97)
Weight at 18 months (kg) 12.0 (9.91, 14.0)
Length at birth (cm) 51.0 (47.8, 55.0)
Length at 3 months (cm) 62.3 (57.4, 65.1)
Length at 18 months (cm) 84.0 (79.7, 88.7)
PI at birth (kg/m3) 26.5 (21.9, 32.0)
PI at 3 months (kg/m3) 27.1 (22.5, 32.9)
PI at 18 months (kg/m3) 20.1 (16.8, 23.3)
aWGA = weight for gestational age was calculated using national standards as
percent deviation from the expected mean (Pihkala et al. [40]), −22% being
equivalent to -2SDs.
bPrematurity = < 259 days of gestation.
Rantakokko et al. Environmental Health 2014, 13:45 Page 3 of 9
http://www.ehjournal.net/content/13/1/45Because growth rates among healthy and cryptorchid
boys may differ, complex samples general linear model
weighted for sampling fractions of boys with (121/55) and
without (5677/55) cryptorchidism from the total cohort
was used to study the association between placenta OTC
concentrations and different anthropometric parameters.
It has been shown that weighting for sampling fractions
can be used for the analysis of case–control data for add-
itional outcomes [39]. Impact of categorised placenta
OTC concentrations on PI, weight and length at birth,
3 months and 18 months, and on weight gain (kg/week)
and length gain (cm/week) between 0–3 months and 3–18
months were explored using weighted general linear
model. Firstly, an analysis across OTC categories without
covariates was performed to test crude associations. Sec-
ondly, an analysis across OTC categories, adjusted for ma-
ternal age at birth, maternal pregnancy body mass index,
diabetes (yes/no) and smoking (yes/no) during pregnancy,
and infant weight for gestational age, was performed.
Weight for gestational age was calculated using na-
tional standards [40]. Most covariates were selected
based on their known association with weight develop-
ment in infancy and childhood. The threshold for stat-
istical significance was set at p < 0.05. Reference groups
for OTC concentrations were <0.1 ng/g fw for DBT
and TBT, <0.02 ng/g fw for TPhT, and <0.25 ng/g fw
for the sum of OTCs.
Information on the duration of total and/or partial
breast feeding was available for 80 of 110 study sub-
jects. A breast feeding index was constructed from these
data for the periods 0–3 months and 3–18 months and in-
cluded as a covariate in an additional weighted general lin-
ear model.
Dioxin and PCB levels have previously been analysed
from the placenta samples of the current study [38]. Be-
cause the sum of dioxin and PCB toxic equivalences
(total-TEQ) in breast milk has been associated with in-
creased early length and weight gain [41], and because hu-
man intake of both OTCs, dioxins, and PCBs is accounted
by the same source, i.e. fish [6,42] possible confounding
was assessed by including log-transformed total TEQ sum
as a covariate in a separate weighted general linear model.
Also Sprearman rank correlation between total-TEQ and
TBT was calculated.
Finally, to study the association between categorised
placenta OTC concentrations and anthropometric pa-
rameters only among the healthy boys (n = 55), analysis
of variance adjusted for maternal age at birth, maternal
pregnancy body mass index and smoking (yes/no) dur-
ing pregnancy, and infant weight for gestational age, was
performed. There were no diabetics among mothers of
healthy boys, and it was thus not included as covariate.
All statistical tests were performed with IBM SPSS Sta-
tistics 21, Armonk, New York, USA.Results
Background characteristics and concentrations of OTCs
in placentas
Population characteristics are given in Table 1 and OTC
concentration in placentas in Table 2. Concentrations of
OTCs were below LOQ in a large proportion of sam-
ples, especially those of MBT (90%), TPhT (57%) and
DBT (35%).
OTCs and weight and length gain from 0 to 3 months
and from 3 to 18 months
Placenta TBT had a significant positive association (p =
0.024) with weight gain from birth to three months when
comparing the third category to the first category, and
similar associations of borderline statistical significance
were observed for DBT and the sum of OTCs (Table 3).
No associations were observed for weight gain between 3
and 18 months. TBT had a significant negative association
(p = 0.042) with length gain between 3 to 18 months, but
this was not consistent across TBT categories and no other
associations with length gain were found (Table 3).
When only healthy boys were included, association of
TBT with weight gain when comparing the third category
Table 2 Percentage of samples < LOQ and concentrations
(ng/g fw) of organotin compounds in placentasa




















aIn the calculation of mean, median and percentiles, LOQ/2 was used for
concentrations less than the LOQ.
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Similar weakening of associations with weight gain when
comparing the third category to first category were ob-
served also for DBT (p = 0.093) and sum of OTCs (0.132).
OTCs and infant PI at birth, 3 months and 18 months
In the unadjusted analysis no significant associations be-
tween placenta OTC concentrations and child PI at any age
were found (data not shown). In the adjusted model, a sta-
tistically significant negative association between DBT and
PI at birth was found, however, not systematically across all
DBT categories. At three and 18 months these associations
were still negative, but did not reach statistical significance
(Table 4). No associations were found between placenta
TBT and PI except for a borderline significant negative as-
sociation at birth that was not systematic across TBT cat-
egories (Table 4). Analysis with healthy boys only did not
materially change these results (not shown).
Inclusion of breast feeding index or total TEQ as co-
variates of regression analysis had little effect on the re-
sults (results not shown). TBT and total TEQ had weak
negative Spearman rank correlation even though it was
of borderline significance (r = −0.174, p = 0.070).
No significant associations were found between OTCs
and child weight, weight for gestational age or length at
any time point (data not shown).Discussion
To our knowledge, this is the first human study on the as-
sociations between OTC exposure and infant growth. The
main finding of this study was that placenta TBT is associ-
ated with increased weight gain during first three 3 months
of life. No statistically significant associations were ob-
served for other OTCs or weight gain between 3 and
18 months.
Increased weight gain in early life may have long-term
consequences due to the well-described association with in-
creased risk of adult obesity [43,44], cardiovascular disease
[45] and non insulin-dependent diabetes mellitus [46]. No
association between PI and OTC exposure was found. PI is
traditionally used in infancy as measure of body propor-
tions in parallel to the use of BMI in older children. How-
ever, it was recently shown that neither PI nor BMI may be
a very sensitive measure of true body fat mass [47].
We have previously described that prenatal exposure to a
mixture of modern pesticides was associated with smaller
birth weight and weight for gestational age, but larger in-
crease in BMI Z-score from birth to school age. However,
as in the current study, absolute measures such as body
weight, length or BMI at school age showed less clear asso-
ciations [41]. In addition, the sum of dioxins and PCB toxic
equivalences in breast milk was associated with lower fat
percentage, lower weight and length at birth, and increased
early length and weight gain Z-score, i.e. rapid catch up
growth. We speculated that the catch up growth associated
with dioxin-like chemicals may partly be explained by a
compensatory biological mechanism following Ah-driven
intrauterine growth restriction [48]. However, adjustment
for total TEQ did not change the results of regression ana-
lysis in our study and also the Spearman rank correlation be-
tween placenta TBT and total TEQ was weak. Thus, dioxin
and PCB exposure measured as chemical levels in the pla-
centas did not explain the associations found in this study.
Prenatal human exposure assessment through measure-
ment of OTCs in placenta is in our opinion a highly valid
approach. Gooke et al. has has performed an extensive
study with Sprague–Dawley rats on the organotin speci-
ation and tissue distribution in dams, fetuses and neonates
following oral administration of TBT. On gestational day
(GD) 20 in the highest exposure group (10 mg/kg bw/d),
the concentrations of TBT and DBT were the highest in
dams’ brain, liver and spleen (1500–1800 ng/g and 400–
1900 ng/g), but were also high in the placenta (650 ng/g
and 300 ng/g). Meanwhile, the levels of TBT and DBT in
liver and brain of fetuses were about half of those in dams.
On GD20, levels of TBT and DBT in placenta were 5-fold
higher than the levels in maternal blood and 10-fold
higher than in milk on post-natal day 6 [49]. Measurement
of OTCs from breast milk samples of Japanese women
[50] and whole blood samples of Finnish fishermen [51],
both high consumers of fish, support the tissue distribution
Table 3 Associations between placenta OTCs and weight/length gain across OTC categories in weighted linear regressiona
Organotin compound Conc. (ng/g fw) Weight gain 0–3 months Weight gain 3–18 months
N Weight gain (kg/week) β (95% CI) p N Weight gain (kg/week) β (95% CI) p
DBT <0.10 31 0.220 ref 27 0.087 ref
0.10–0.14 30 0.222 0.016 (−0.011, 0.044) 0.23 26 0.082 −0.007 (−0.020, 0.006) 0.29
≥0.15 41 0.230 0.021 (0.000, 0.043) 0.054 33 0.079 −0.009 (−0.020, 0.002) 0.11
TBT <0.10 31 0.224 ref 26 0.086 ref
0.10–0.4 39 0.217 0.005 (−0.018, 0.029) 0.64 34 0.084 −0.007 (−0.022, 0.008) 0.36
>0.4 32 0.235 0.024 (0.003, 0.044) 0.024 26 0.078 −0.011 (−0.024, 0.003) 0.12
TPhT <0.02 60 0.227 ref 49 0.080 ref
≥0.02 42 0.220 0.005 (−0.016, 0.027) 0.62 37 0.085 0.002 (−0.008, 0.011) 0.74
Sum of OTCs <0.25 26 0.220 ref 22 0.083 ref
0.25–0.50 31 0.228 0.025 (−0.002, 0.052) 0.065 27 0.086 <0.001 (−0.016, 0.016) 1.00
>0.50 45 0.225 0.018 (−0.001, 0.037) 0.062 37 0.080 −0.008 (−0.021, 0.005) 0.21
Organotin compound Conc. (ng/g fw) Length gain 0–3 monhts Length gain 3–18 monhts
N Length gain (cm/week) β (95% CI) p N Length gain (cm/week) β (95% CI) p
DBT <0.10 32 0.83 ref 28 0.34 ref
0.10–0.14 30 0.83 0.054 (−0.038, 0.146) 0.25 26 0.33 −0.014 (−0.039, 0.010) 0.25
≥0.15 41 0.83 0.047 (−0.021, 0.114) 0.18 33 0.33 −0.008 (−0.027, 0.011) 0.42
TBT <0.10 32 0.82 ref 27 0.34 ref
0.10–0.4 39 0.83 −0.015 (−0.085, 0.055) 0.67 34 0.33 −0.025 (−0.048, −0.001) 0.042
>0.4 32 0.84 0.024 (−0.038, 0.085) 0.45 26 0.34 −0.014 (−0.036, 0.009) 0.22
TPhT <0.02 60 0.83 ref 49 0.34 ref
≥0.02 43 0.83 −0.005 (−0.061, 0.051) 0.86 38 0.34 −0.006 (−0.025, 0.013) 0.54
Sum of OTCs <0.25 27 0.84 ref 23 0.34 ref
0.25–0.50 31 0.82 0.012 (−0.084, 0.108) 0.81 27 0.34 −0.012 (−0.042, 0.018) 0.41
>0.50 45 0.83 0.018 (−0.039, 0.076) 0.53 37 0.33 −0.012 (−0.035, 0.010) 0.29




















PI at birth PI at 3 months PI at 18 monhts
N mean PI (kg/m3) β (95% CI) p N mean PI (kg/m3) β (95% CI) p N mean PI (kg/m3) β (95% CI) p
DBT <0.10 33 26.8 ref 31 27.5 ref 28 20.1 ref
0.10–0.14 30 26.0 −1.46 (−2.56, −0.35) 0.010 26.7 −1.35 (−2.77, 0.08) 0.063 20.0 −0.79 (−2.36, 0.79) 0.32
≥0.15 42 27.4 −0.45 (−1.55, 0.66) 0.43 30 41 28.2 −0.10 (−1.15, 1.13) 0.99 26 33 20.0 −0.93 (−2.04, 0.18) 0.098
TBT <0.10 33 26.5 ref 31 27.4 ref 27 20.0 ref
0.10–0.39 40 26.6 −1.36 (−2.90, 0.18) 0.084 39 26.9 −0.28 (−1.79, 1.24) 0.72 20.2 0.46 (−0.97, 1.90) 0.52
≥0.40 32 27.5 −0.26 (−1.63, 1.12) 0.71 32 28.5 0.85 (−0.20, 1.90) 0.11 34 26 19.9 −0.38 (−1.33, 0.57) 0.43
TPhT <0.02 61 27.0 ref 60 27.9 ref 49 20.1 ref
≥0.02 44 26.6 −0.75 (−1.56, 0.06) 0.068 42 27.0 −0.24 (−1.20, 0.73) 0.63 38 20.1 0.21 (−0.67, 1.09) 0.63
Sum of OTCs <0.25 27 27.1 ref 26 27.3 ref 23 19.8 ref
0.25–0.49 32 26.0 −1.23 (−2.69, 0.24) 0.10 31 27.2 0.57 (−1.03, 2.16) 0.48 20.3 1.33 (−0.31, 2.97) 0.11
≥0.50 46 27.3 −0.53 (−1.79, 0.74) 0.41 45 27.9 0.42 (−0.59, 1.43) 0.41 27 37 20.0 −0.33 (−1.27, 0.60) 0.48
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tained mainly non-detectable levels of TBT and barely de-
tectable level of DBT (milk) and TPhT (blood). Thus,
placenta tissue may be ideal to reflect true foetal exposure.
However, as in urine, where the concentration of TBT me-
tabolites decreased rapidly during the first days after volun-
tary ingestion of OTCs [52,53], OTCs may be rather quickly
eliminated also from placenta. This may present a problem
for intake estimation if maternal intake of OTCs varies a lot
during pregnancy. Generally, body distribution of charged
OTCs appears to be different from that of classical neutral
POPs that are preferentially stored in lipid rich tissues in-
cluding milk. This behaviour may explain why adjustment
for breast feeding did not have any impact on the results.
From the mechanistic point of view, TBT is described as
a high affinity agonist of PPAR-γ and retinoid X receptor
(RXR), two important nuclear receptors during adipocyte
differentiation [26]. An antagonist study has confirmed
the importance of PPAR-γ in the TBT-induced adipocyte
differentiation [24]. Also a recent study on the molecular
mechanisms of TBT obesogenicity using microarray ana-
lysis in the 3 T3-L1 in vitro system revealed enrichment of
Gene Ontology terms involved in energy and fat metabolism,
and pathway analysis unveiled PPAR signaling as the most
significantly enriched pathway [54]. Based on our results, the
observed associations between OTC concentrations in pla-
centa and infant weight gain, if real, was mainly due to TBT
as DBT is a debutylation product of TBT [34]. In addition,
the obesogenic potential of TBT through RXRα/PPARα is
much stronger than that of DBT [26]. TPhT may also con-
tribute as it has similar RXRα/PPARα affinity as TBT
[23,26], but its concentration in our placenta samples was at
least an order of magnitude less than that of TBT.
Estimated average dietary intake for the sum of four
OTCs specified by European Food Safety Authority (DBT,
TBT, TPhT and dioctyltin (DOT)) in Finland is about
3 ng/kg body weight (bw) per day [6,55]. The Tolerable
Daily Intake (TDI) of 250 ng/kg bw for OTCs based on their
immunotoxicity [5], is 80 times higher. In the worst case
scenario of high consumption of contaminated fish the in-
take for women increases to 120 ng/kg body weight per day
[55]. There are reasons to believe that the maternal intake
of OTCs in the current study was quite high. Firstly, con-
sumption of local fish that was heavily contaminated with
OTCs during the time of sample collection [56] may have
resulted in a high intake. Secondly, in another Finnish study
TBT concentrations in placenta samples collected in 2004–
2005 from the inland city of Kuopio were much lower, all
less than the LOQ of 0.20 ng/g fw in that study [57].
The relationship between PI, used as metrics of adiposity
in the current study, and OTC exposure can be compli-
cated. In experiments with C57BL/6 J mice daily prenatal
TBT exposure of 50–500 μg/kg by intraperitoneal injection
from embryonic day 12 until the day before deliverysignificantly increased adipose mass in TBT-treated males
by 20% over controls. However, growth curves for TBT-
treated pups showed a slight trend for lower total body
weight that was statistically not significant. TBT may thus
increase body adiposity without overtly increasing total
body weight [26]. Using the same mice strain a single pre-
natal TBT exposure of 100 μg/kg by gavage on embryonic
day 16.5 led to a 2-fold increase in the total lipid accumula-
tion (from 20% to 40%) compared with controls [25]. Ma-
ternal exposure in these animal experiments thus appears
to be 1000 times higher than that of mothers in our study.
This study has several limitations. Firstly, the number of
subjects was rather small increasing the risk of chance
finding. Secondly, the cohort used was originally planned
for the study of congenital malformations, not for the out-
comes studied here. This limitation was accounted for by
using a weighted general linear model approach [39]. Re-
garding these limitations, we note that the significant asso-
ciation between placenta TBT and weight gain turned into
borderline significant when only healthy boys were in-
cluded in the analysis. Thirdly, we used PI as a measure of
infant adiposity in lack of a better biomarker. Animal and
in vitro experiments refer to the importance of specific
adiposity measurements, but unfortunately this was not
available at the time the cohort was investigated.
Conclusions
We observed that placenta TBT concentration was associ-
ated with increased weight gain during the first three
months of life of newborn boys, suggesting a possible obe-
sogenic effect. No clear associations were observed between
placenta OTCs and infant PI during the first 18 months of
life. The results should be interpreted with caution, because
the number of study subjects included in this study was
limited. The study should be repeated with a larger number
of subjects, more specific biomarkers of adiposity and lon-
ger follow up time.
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